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mutation. The sensitivity and specificity of Cobas 4800 BRAF V600 in vitro diag-
nostic test is excessively high to detect the V600 mutation. In the BRIM-3 study, 
vemurafenib showed improved PFS and OS in patients carrying BRAF mutation. 
Our aim is to analyze the vemurafenib international and local real-life survival data 
of the patients treated in the National Institute of Oncology, in case of individual 
reimbursement application. Methods: We retrospectively assessed the single 
centre Hungarian real-life survival data from 2012 to May 2015. We compared the 
outcome of the Hungarian and the French real-life and BRIM-3 data. Results: In 
the selection of the patient group suitable for BRAFi therapy, we carried out 277 
BRAF mutation analysis with Cobas test during the given period. 148 cases were 
wide type, the mutation rate was 46,57% with 129 mutant cases. In Hungary, BRAFi 
therapy is reimbursed, only on the basis of individual reimbursement application. 36 
MM patients were enrolled, with median age of 53,5 years. The median PFS reached 
5,4 months, the OS reached 12,3 months. In the previously published French single 
centre trial, in temporary authorisation program, the median PFS was 3,6 months, 
the median OS was 7,5 months. The BRIM-3 study demonstrated mPFS 6,9 months 
and OS 13,6 months. ConClusions: The detection of BRAF mutation is essential 
in the therapeutic strategy of metastatic melanoma patients. The Cobas 4800 BRAF 
test allows a more exact selection of the patient group to be treated by BRAFi. 
Our single centre OS data are close to BRIM3 clinical trial data. In case of previous 
vemurafenib therapy started in appropriate treatment line, further improvement 
can be expected in survival results.
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objeCtives: To estimate the budget impact in Belgium of denosumab (120 mg) 
in the treatment of GCTB, an extremely rare, locally aggressive benign tumor 
often leading to severe destruction of bone and extension into the surround-
ing soft tissues. Methods: A budget impact model was developed, combining 
epidemiological data, proportions of resectable and unresectable GCTB disease, 
and eligibility for treatment with denosumab. Evidence collected in clinical tri-
als is used to estimate the denosumab clinical effect. Publicly available costs of 
the relevant surgical procedures and the actual cost for denosumab 120 mg from 
payer perspective are considered. The clinical effect of denosumab in delaying 
or downgrading invasive surgeries is estimated by comparing the surgical pro-
cedures planned at trial entry and the procedures actually performed during the 
trial. To calculate the savings in surgical procedures, the downgrade in planned 
procedures and only 50% of the avoided procedures in the trial period were con-
sidered. Resource use associated with the surgical procedures included the need 
for rehabilitation and re-hospitalizations due to complications. Savings were only 
applied to patients with resectable tumors. The model does not take into account 
the full clinical benefit of denosumab including decrease in disease progression 
in patients who have not undergone surgery. The time horizon considered was 3 
years. Results: Denosumab is expected to be provided to 32, 42 and 53 patients in 
year 1, 2 and 3, respectively. 550,940 euros of total drug expenditure are expected. 
Savings were estimated at 409,372 euros, the majority of which was attributable 
to fewer and less severesurgical procedures. The impact of denosumab on the 
overall health care budget is 141,568 euros over three years. ConClusions: The 
introduction of denosumab in the treatment of GCTB has a manageable budget 
impact in Belgium. Seventy four percent of the denosumab expenditure is off-set 
thanks to its clinical benefit.
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BudgET ImPACT ANAlySIS of dASATINIB AS A SECoNd-lINE ThERAPy IN 
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objeCtives: CML is among seven nosologies included in the federal program 
for supply of medicines to patients with rare diseases in the Russian Federation. 
Currently only first-generation tyrosine kinase inhibitor - imatinib is available to 
CML patients within this program. However from 25% to 30% of CML patients in 
Russia have intolerance or develop resistance to imatinib and require second line 
therapy with dasatinib or nilotinib. Methods: This study includes budget impact 
analysis (BIA) for dasatinib as a second-line CML therapy. Only direct pharmaco-
therapy costs were considered. Annual treatment cost of dasatinib amounts to 
1,720,111 rubles (28,365 € ) for chronic phase. Time horizon was set at 1 year. In 
the baseline scenario it was assumed that 100% of the imatinib-resistant patients 
are treated with high-dose imatinib in frame of the federal “seven nosologies” 
program. In the future scenario upon dasatinib inclusion into aforementioned 
program the percentage of patients that would be possible to switch from high-
dose imatinib to dasatinib without increase of the total national CML budget was 
calculated. Also annual economic impact of providing dasatinib as a second-line 
therapy to 100% of the eligible patients was estimated. Assumptions regarding 
adherence to treatment of patients diagnosed with CML and actual medica-
tion consumption rate were included into analysis. Results: Budget impact 
analysis was carried out for a total population of 7100 patients according to the 
national CML registry in 2015. Centralized purchase of dasatinib in frame of the 
federal program could save 463 mln rubles (7,7 mln € ) or 10% of the actual total 
CML budget in Russia. ConClusions: With consideration for actual dasatinib 
use within regional drug provision programs it was demonstrated that 100% of 
the imatinib-resistant and intolerant patients can be provided with dasatinib 
using Kaplan-Meier estimates. Additional data from the Dutch Comprehensive 
Cancer Centres (stage IV only) were used to compare survival outcomes in two 
time periods (2003-2011 versus 2012-2015). Results: From 2012-2015, 1259 patients 
received systemic treatment (median follow-up 12.6 months; data cut-off March 
09, 2015). The most frequently prescribed treatments were ipilimumab (29%) and 
vemurafenib (29%), followed by trial-based treatments (27%), chemotherapy (11%), 
and dabrafenib (4%). Vemurafenib was the most frequently applied treatment in the 
first line (41%), ipilimumab in the second line (56%), and trial-based treatments in 
the third and fourth line (41% and 63%, respectively). The median TTNT was 5.4, 4.7 
and 4.3 months in the first, second, and third line, respectively. The median OS was 
9.6 months (IQR 4.6-18.6) and the one-year survival was 41% (unresectable stage IIIc 
[n= 33]: median OS 32.8 months, one-year survival 71%; stage IV [n= 1226]: median 
OS 9.3 months, one-year survival 40%). In contrast, survival outcomes of stage IV 
melanoma were much lower in the period before the introduction of new drugs 
(2003-2011: median OS 6.8 months, one-year OS 33%). ConClusions: Melanoma 
survival has improved since the introduction of new drugs for advanced melanoma. 
The survival gain shown in pivotal trials was also observed in real-world clinical 
practice in The Netherlands.
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CoNTRIBuTIoN of SPECIfIC dISEASES, CohoRTS ANd CodINg ChANgES To 
oVERAll moRTAlITy ImPRoVEmENT
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objeCtives: Identifying the drivers of trends in mortality for disease classes is 
challenging. We used the Requiem model to visualise trends by gender and age 
in 3-D format to identify cohort and other effects in specific cancers. Methods: 
The Requiem model analysed and smoothed ONS mortality statistics for England 
and Wales from 1970 to 2013 by single year of age and gender. Disease codes were 
mapped at 4-digit level from ICD-8 to ICD-10 by medical modellers. An analysis 
was run for total cancer mortality and individual malignant diseases within that 
category. Outputs were displayed in multiple formats, including 3-D images of cen-
tral mortality and deaths by age over time, and heat maps of absolute mortality 
improvement per disease and the component each disease contributed to all-cause 
mortality trends. Results: Cancer mortality increased from 1970 to 1990s and has 
since fallen by up to 4% per year, accounting for a 1-2% of absolute improvement 
in all-cause mortality, and with evidence from heat maps for cohort effects. Most 
cancers showed increasing mortality rates to the 1990s, which have now declined. 
This is seen particularly in men in lung cancer, which saw up to 10% improvement 
per year in mortality, in breast cancer in women, with a peak in the 1980s and up 
to 20% annual improvement since then, and in colon cancer in both genders, with 
a 5-10% annual improvement in mortality per year. Hodgkin’s lymphoma mor-
tality has decreased steadily in both genders, while non-Hodgkin’s mortality has 
increased in the over 50s. Mortality continues to worsen for liver, kidney and CNS 
cancers. Pancreatic cancer has shown little change in mortality since 1970 in either 
gender. ConClusions: The Requiem model 3-D visualisation facilitates the under-
standing of trends in mortality for different cancers, and shows the impact of cohort 
effects and risk factors such as smoking and alcohol.
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objeCtives: Ipilimumab is licensed for the treatment of adults with advanced (unre-
sectable or metastatic) malignant melanoma. It was approved for reimbursement in 
Ireland in 2012, through the Oncology Drug Management System (ODMS). The ODMS 
was introduced by the National Cancer Control programme in July 2012. The scheme 
allows direct hospital reimbursement for approved high cost anti-cancer drugs 
for individual patients. Drugs must be prescribed for approved indications accord-
ing to license informed protocols. The online based system is designed to collect 
information from hospitals (26 nationally) in relation to patient demographic data, 
cancer drug use and spending. This data is maintained by the payer (Primary Care 
Reimbursement Service (PCRS)). The objective of this study is to examine this real 
world data of patients treated with ipilimumab. Methods: The PCRS extracted data 
on all patients who had received ≥ 1 dose of ipilimumab ( June 2012 - May 2015) in the 
public hospital setting through the ODMS. Patient data included patient demograph-
ics, the quantity of ipilimumab supplied and the reimbursement claim data. The 
National Centre for Pharmacoeconomics analysed this anonymised data. Kaplan-
Meier survival curves were constructed using the Tierney et al methodology. Survival 
data was extrapolated using the Hoyle and Henley methodology. Results: A total 
of 205 patients who had received ≥ 1 dose ipilimumab over the period of analysis 
were identified. The mean age of the cohort was 60.4 years (SD ±14) and 58.5% were 
male. All 4 cycles of ipilimumab were received by 59% of patients. Seven patients 
were re-treated with the drug. Empirical and extrapolated real world survival data 
were compared to clinical trial evidence. ConClusions: The analysis provides 
real world survival outcomes for patients with advanced malignant melanoma 
treated with ipilimumab in Ireland. Examination of this evidence is prudent in 
advance of the launch of the PD1 inhibitors for malignant melanoma.
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objeCtives: The selection of the MM patient group, eligible for BRAFi therapy is 
based on the molecular pathologic diagnostics of the BRAF V600 gain-of-function 
